Overview

Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Estimate the effect of oral ketoconazole administration (400 mg once daily over 3 days) on the pharmacokinetics (process by which the drug is absorbed, distributed, metabolized, and eliminated by the body) of single 10 mg dose of tasocitinib (CP-690,550) in normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Ketoconazole
Tofacitinib